AMAM News and Press, Ambrx Biopharma Inc. American Depositary Shares (each representing seven) From 01/09/24

2024-01-09 06:00:00 ET Summary Johnson & Johnson has announced plans to acquire Ambrx, a clinical-stage biopharmaceutical company specializing in antibody drug conjugates (ADCs), for ~$2.0 billion. ADCs have become a popular investment for big pharma companies, with Pfizer, Ab...

2024-01-08 12:31:25 ET Gainers: Harpoon Therapeutics ( HARP ) +112% . Ambrx Biopharma ( AMAM ) +101% . Nkarta ( NKTX ) +47% . Mountain Crest Acquisition Corp IV ( MCAF ) +45% . Spectaire Holdings ( SPEC ) +43% . Neximmune ( ...

MONSEY, N.Y., Jan. 08, 2024 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating the fairness of the price of $28.00 per share in cash pursuant to which Ambrx Biopharma, Inc. (Nasdaq: AMAM) (“Ambrx”) has agreed to be sold to Johnson & Johnson (“JNJ...

2024-01-08 08:53:00 ET U.S. stock index futures on Monday pointed to a mixed open for Wall Street, as the first full trading week of the new year begins. The benchmark S&P 500 ( SP500 ) last week was unable to extend its blistering year-end 2023 rally. Here are some stocks to wa...

2024-01-08 07:52:26 ET More on Johnson & Johnson Johnson & Johnson: Overblown Stelara Concerns Distract From Value Johnson & Johnson's Bullish Outlook: Surprising Strength You Shouldn't Overlook Johnson & Johnson: A Defensive Dividend King Set To Outp...

SAN DIEGO, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Ambrx Biopharma, Inc., or Ambrx (NASDAQ: AMAM), today announced that it has entered into a definitive agreement pursuant to which Johnson & Johnson will acquire all of the outstanding shares of Ambrx for $28.00 per share in cash, representing an ap...

2024-01-06 01:06:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

SAN DIEGO, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Ambrx Biopharma, Inc., or Ambrx, (NASDAQ: AMAM), today announced that the Company will be added to the NASDAQ Biotechnology Index (NASDAQ: NBI), effective prior to the market open on Monday, December 18, 2023. “2023 has been a transformati...

Cohort 9 Following completion of the 21-day observation period at 3.4 mg/kg (Cohort 9), no dose limiting toxicities (DLTs) or serious adverse events (SAEs) were observed Two patients in Cohort 9 experienced rapid PSA reduction at three weeks post-treatment following the first ...

2023-11-21 05:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...